Thalomid

Known as: Celgene Brand of Thalidomide 
 

Topic mentions per year

Topic mentions per year

1998-2015
024619982015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma… (More)
Is this relevant?
Review
2001
Review
2001
The sedative/hypnotic thalidomide was withdrawn from the worldwide market nearly 40 years ago, because of its teratogenic and… (More)
Is this relevant?
Review
2001
Review
2001
Loss of appetite and weight predict a poor prognosis for cancer patients. Although caloric supplementation might benefit… (More)
Is this relevant?
2000
2000
Thalomid is the FDA-approved commercial formulation of thalidomide currently used in the US to treat erythema nodosum leprosum, a… (More)
Is this relevant?
2000
2000
Thalidomide (Thalomid) is approved for use in the US to treat complications from leprosy. Peripheral neuropathy is a dose… (More)
Is this relevant?
Review
2000
Review
2000
Although melanoma is a relatively chemoresistant malignancy, systemic chemotherapy remains the primary treatment for metastatic… (More)
Is this relevant?
Review
2000
Review
2000
Recent evidence suggests that angiogenesis is increased in multiple myeloma and has prognostic value in the disease. Based on the… (More)
Is this relevant?
Review
2000
Review
2000
Investigators at the Royal Marsden Hospital and University College in London have studied thalidomide (Thalomid) as both low-dose… (More)
Is this relevant?
Review
2000
Review
2000
Angiogenesis is essential to prostate cancer progression. The first study of antiangiogenic therapy in patients with locally… (More)
Is this relevant?
1998
1998
  • Positively aware : the monthly journal of the…
  • 1998
The FDA has approved the use of Thalidomide (Thalomid) for treating a leprosy-associated condition. However, Thalidomide can also… (More)
Is this relevant?